-- Hadasit Surges Most in Three Months After Unit Gets FDA Approval
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-02-28T09:14:45Z
-- http://www.bloomberg.com/news/2012-02-28/hadasit-surges-most-in-three-months-after-unit-gets-fda-approval.html
Hadasit Bio-Holdings Ltd. (HDST)  surged the
most in almost three months after a unit got investigational new
drug approval from the U.S. Food and Drug Administration for a
Phase II clinical trial for blood clotting.  Shares of the developer of diagnostic and treatment
products rallied 10 percent to 0.56 shekel, the most since Dec.
1, at 11:04 a.m. in  Tel Aviv .  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  